Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), adalimumab (ADA) in patients with psoriatic arthritis...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Formáid:	Artigo
Teanga:	Russo
Foilsithe / Cruthaithe:	IMA-PRESS LLC 2021-06-01
Sraith:	Современная ревматология
Ábhair:	psoriatic arthritis tofacitinib adalimumab biologic disease-modifying antirheumatic drug targeted synthetic disease-modifying antirheumatic drug remission minimal disease activity
Rochtain ar líne:	https://mrj.ima-press.net/mrj/article/view/1145
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!